Keytruda (pembrolizumab) is an immunotherapy drug (PD-1 inhibitor) used to treat numerous cancers, including NSCLC, melanoma, and head and neck squamous cell carcinoma. It works by blocking the PD-1 pathway, allowing the immune system to detect and attack cancer cells.
Common side effects include fatigue, rash, diarrhea, and nausea. It is administered via intravenous (IV) infusion, typically every 3 or 6 weeks
